Definium Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

DFTX$34.64-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

	Three Months Ended September 30,		Nine Months Ended September 30,
(in thousands, except share and per share amounts)	2026	2025	2026	2025
Operating expenses:
Research and development	$46,141	$30,978	$136,290	$84,144
General and administrative	26,138	14,691	70,286	34,587
Total operating expenses	72,279	45,669	206,576	118,731
Loss from operations	(72,279)	(45,669)	(206,576)	(118,731)
Other income/(expense):
Interest income	10,139	2,262	17,183	7,469
Interest expense	(1,150)	(1,274)	(3,628)	(4,214)
Foreign exchange loss, net	(21)	(39)	(97)	(107)
Change in fair value of 2022 USD Financing Warrants	12,350	(22,545)	(93,927)	(17,774)
Total other income/(expense)	21,318	(21,596)	(80,469)	(14,626)
Net loss	(50,961)	(67,265)	(287,045)	(133,357)
Other comprehensive loss
Unrealized gain/(loss) on investments	(1,245)	196	(1,913)	242
Loss on foreign currency translation	(1)	(2)	(1)	(60)
Comprehensive loss	$(52,207)	$(67,071)	$(288,959)	$(133,175)
Net loss per common share, basic	$(0.37)	$(0.78)	$(2.42)	$(1.56)
Net loss per common share, diluted	$(0.46)	$(0.78)	$(2.42)	$(1.56)
Weighted-average common shares, basic	135,941,973	85,885,516	118,571,999	85,436,678
Weighted-average common shares, diluted	137,346,685	85,885,516	118,571,999	85,436,678

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.